Biotechnology company Amgen Inc. posted an 11 percent drop in third-quarter profit on flat sales and higher operating costs, although the drugmaker still beat expectations.
Bristol-Myers Squibb Co. posted a slight decline in third-quarter profit as its restrained spending was offset by flat sales of its drugs, lower income from its partners and bigger discounts to government due to the health care overhaul.
Merck KGaA announced that the two-year Phase 3 REFLEX study met its primary endpoint by demonstrating that Rebif (interferon beta-1a) significantly delayed conversion to multiple sclerosis diagnosed according to the McDonald criteria.
Venture-backed pharmaceutical company Hatchtech Pty Ltd has concluded a $6.3 million capital raising to conduct a Phase 2a clinical trial for its very promising head lice treatment.
ARIAD Pharmaceuticals, Inc. announced interim results of a randomized, open-label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer.
Shire plc announces that it has received a Paragraph IV Notice Letter from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire’s 4 mg guanfacine hydrochloride extended release tablet, INTUNIV.
PTC Therapeutics, Inc. announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia.
Rockland Immunochemicals Inc. announced that it has received a Phase 1 Small Business Innovation Research grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
Agile Therapeutics announced results from a Phase 2 clinical study of AG200-15, Agile’s weekly contraceptive patch containing ethinyl estradiol in combination with levonorgestrel.
Beckman Coulter, Inc.’s flow cytometry analysis software, Kaluza 1.1, processes multicolor files of up to 10 million events in real time and offers an analytical speed that is several hundred times faster than other commercially available software.
Tosoh Corporation announced several high performance liquid chromatography columns for the analysis of water-soluble polymers, as well as a column designed for the simultaneous separation of an active pharmaceutical ingredient and its counterions.
A researcher has discovered what could be the first truly effective breakthrough in the diagnosis and treatment of pulmonary hypertension, a devastating, life-threatening condition which results in an enlargement of the heart.
By studying the brain circuits that control bird song, MIT researchers have identified a "chain reaction" of brain activity that appears to control the timing of song.
Antigenics, Inc. announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.
New Phase 3 data indicate that Menveo demonstrated robust immunogenicity in infants potentially offering protection against four major serogroups of meningococcal disease.